|
|
|
|
|
Bicalutamide
drug data and news
Bicalutamide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Bicalutamide | ||
| Brand Names/Synonyms | Bicalutamide; Bicalutamide [Usan:Ban:Inn]; Casodex | ||
| Indication | For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. | ||
| Mechanism Of Action | Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. | ||
| Bicalutamide News (When available) |
Advances in Early-Stage Prostate Cancer 06 Mar 2006 New Published Data[1] Show That Bicalutamide (Casodex) 150mg Plus ... Jan 31, 2006 Bicalutamide 150mg Plus Radiotherapy Significantly Extends ... Feb 1, 2006 The Early Prostate Cancer Trial And Adjuvant Anti-androgen Therapy ... Feb 25, 2006 ASCO 2006 Prostate Cancer Symposium - Session on The Treatment of ... Mar 3, 2006 Consiga la Gold Card American Express ahora Jan 31, 2006 (PRN) - Millennium Announces Cash Tender Offer for Its 7.00% ... Jan 31, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antineoplastic Agents; ATC:L02BB03 | ||
| Absorption | Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. | ||
| Interactions |
Interactions for Bicalutamide: In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites. It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide | ||
| Chemical Formula | C18H14F4N2O4S | ||
| Molecular Weight | 430.374 g/mol | ||
| Smiles String | CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O | ||
| Melting Point | 191-193 °C | ||
| Water Solubility | 5 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 3.049 | ||
| Isoelectric Point | 12 | ||
| Biotransformation | Bicalutamide undergoes stereo specific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation. | ||
| Half Life | 5.9 days | ||
| Protein Binding [%] | 96% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Bicalutamide.html http://www.rxlist.com/cgi/generic3/bicalutamide.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00042 | ||
| CAS Registry Number | 90357-06-5 | ||
| KEGG Compound ID | C08160 | ||
| PubChem ID | SID:193420 | ||
| PharmGKB ID | PA448616 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2184478 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |